KIF20A and gastric neoplasm: This discovery laid the groundwork for further exploration into the immunotherapeutic utility of KIF20A, as evidenced by Osawa et al., who broadened the understanding by identifying HLA-A*2402-restricted epitope peptides from KIF20A, further underscoring its significance in pancreatic and stomach cancers [90].